Hornehebert0151
The production of nanocellulose for drug delivery systems has achieved increased attention in the past decade. High capacity for swelling and absorption of the liquid phase, high flexibility in creating different derivatives, economical cost and ease of access to the primary source, all of these properties have encouraged researchers to use nanocellulose and its derivatives as a highperformance drug carrier.
We summarize the recent progresses of cellulose-based nanocarriers designing and practical approaches in drug delivery.
We conducted a literature review on the development of the nanocellulose and its derivatives as a highperformance drug carrier.
In this review, we have attempted to present the latest advances in cellulose modifications for the design of pharmaceutical nanocarriers. at first, cellulose properties and structural classification of nanocellulose were introduced. Then, focusing on medical applications, some efforts and laboratory trials in cellulose-based nano designing were also discussed. The findings demonstrate the benefits of nanocellulose in drug delivery and its potential for modifying by adding functional groups to enhance drug delivery efficiency. Due to the physical and chemical properties of cellulose and its high flexibility to interact with other compounds, a broad perspective can be imagined in the diverse research and novel forms of nanocarriers.
The cellulose nanocarriers can be considered as an attractive platform for researchers to design new structures of pharmaceutical carriers and increase the efficiency of these nanocarriers in drug delivery for the treatment of diseases such as cancer.
The cellulose nanocarriers can be considered as an attractive platform for researchers to design new structures of pharmaceutical carriers and increase the efficiency of these nanocarriers in drug delivery for the treatment of diseases such as cancer.
Inflammation is a key element in tumor progression, over time, persistent inflammation causes damage to DNA and leads to cancer. The relationship between chronic inflammation and tumor development is well established, blocking of which can help in cancer prevention and treatment in the future.
Hence, with this background, the present study aims to evaluate the anti-inflammatory and anticancer potential of Cassia auriculata (CA) solvent fractions through in silico and in vitro means, respectively.
Generally, inflammatory mediators play a key task in chronic inflammation, following its inflection was chosen for their interactions with nine structurally varied phytoconstituents of CA identified through GCMS. The ethanolic extract of CA was assessed for its apoptotic effects on A549 lung cancer cells by 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, JC-10 staining, DNA fragmentation assay and quantitative Real-Time Polymerase Chain Reaction (qRT-PCR).
The interactions between chemotherapy.
In the present study, polymer-drug conjugates were synthesized based on azo-bond cleavage drug delivery approach for targeting erlotinib as an anticancer drug specifically to the colon for the proficient treatment of colon cancer.
Colon Cancer (CC) is the third commonly detected tumor worldwide and makes up about 10% of all cases of cancers. this website Most of the chemotherapeutic drugs available for treating colon cancer are not only toxic to cancerous cells but also to the normal healthy cells. Among the various approaches to get rid of the adverse effects of anticancer agents, prodrugs are one of the most imperative approaches.
The objective of the study is to chemically modify the erlotinib drug through azo-bond linkage and suitable spacer which will be finally linked to the polymeric backbone to give the desired polymer linked prodrug. The azo reductase enzyme present in the colon is supposed to cleave the azo-bond specifically and augment the drug release at the colon.
The synthesized conjugates were charahosphazene linked drug conjugates of erlotinib could be promising candidates for the site-specific treatment of colon cancer with the least detrimental side-effects.
These studies indicate that polyphosphazene linked drug conjugates of erlotinib could be promising candidates for the site-specific treatment of colon cancer with the least detrimental side-effects.
The growing prevalence of cancer and the resulting chemoresistance exert not only a great healthcare burden but is also a great challenge to public health, worldwide. In search of new chemical entities against cancer, triazine hybrids of stilbene scaffold were investigated for their anticancer potential.
Synthetic triazine hybrids of stilbene were used for determination of their anticancer potential for cervical (HeLa) and breast (MCF-7) carcinoma cells. Hit compound (7e) namely, sodium (E)-6,6'-(ethene-1,2-diyl)bis(3- ((4-chloro-6-((3-luorophenyl)amino)-1,3,5-triazin-2-yl)amino)benzenesulfonate) was explored further for mechanistic studies.
In a set comprised of twelve derivatives, compound, sodium (E)-6,6'-(ethene-1,2-diyl)bis(3-((4-chloro-6-((3- luorophenyl)amino)-1,3,5-triazin-2-yl)amino)benzenesulfonate) (7e) was found most active against HeLa and MCF-7 cells. The present study has revealed that compound 7e may activate mitochondrial pathway of apoptosis in HeLa and MCF-7 cells which was assessed by DNA binding studies, estimation of release of Lactate Dehydrogenase (LDH), fluorescence imaging, production of Reactive Oxygen Species (ROS) in cancer cells, analysis of cell cycle by flow cytometry, change in Mitochondrial Membrane Potential (MMP) and activation of caspase-9 and caspase-3, respectively.
Compound 7e may serve as a lead in designing new anticancer compounds from stilbene scaffold.
Compound 7e may serve as a lead in designing new anticancer compounds from stilbene scaffold.
Searching for new cytotoxic agents with apoptosis induction may represent a viable strategy for cancer treatment to overcome the increased resistance to available anticancer agents.
The purpose of the current study was aimed at preparation and anticancer evaluation of two new series of 2H-quinolinone and halogenated 2H-quinolinone derivatives against two cancer cell lines.
Two new series of 2H-quinolinone and halogenated 2H-quinolinone derivatives were prepared and screened for their cytotoxicity against breast MCF-7 and liver HepG-2 cancer cell lines as well as normal breast MCF-10a.
The tested molecules revealed good cytotoxicity and selectivity toward cancer cell lines relative to normal cells. These compounds were analyzed by DNA flow cytometry on MCF-7 cells. They were found to cause G2/M phase arrest and induced apoptosis at the pre-G1 phase. In addition, increased caspase 3/7 activity and decreased osteopontin expression verified the apoptotic activity.
The potent compounds discovered in this study can be a hit for the discovery of new cytotoxic agents and are worthy of further investigation.
